National Contracts Disclaimer


NCD 2022/23


Ardens can support practices and PCNs in many ways on SystmOne with the delivery of the Network Contract DES (NCD) as detailed below.  The NCD DES dashboard will also be available on Ardens Manager


The PCN DES template hosts the code clusters alongside links to the corresponding templates.  Access the main template by going to 'Auto-Consultation > Contracts > NCD PCN DES'.  Make it easier to quickly access this template by adding it to your F12 favourites

       


The Reports can be found under 'Clinical Reporting > Ardens > Contracts | 2022 23 | NCD'


 

Additional Support Articles

The following support articles will also provide further information about supporting resources on Ardens:




Additional Roles Reimbursement Scheme (ARRS)

 

The following roles can all be supported by Ardens:

 

These individual templates can be found via 'Auto-Consultation > ardens OTHER PROFESSIONALS



 


Investment and Impact Fund (IIF)

Below is a summary of the Investment and Impact Fund (IIF) indicators:


Improve prevention and tackle health inequalities

  1. CVD-01: Percentage of patients aged 18+ with elevated BP reading (≥ 140/90mmHg) and not on the QOF hypertension register, for whom there is evidence of clinically appropriate follow-up to confirm or exclude a diagnosis of hypertension (71 points).
  2. CVD-02: Percentage increase in number of patients on QOF hypertension register (35 points).
  3. CVD-03: Percentage of patients aged 25 - 84 years with a CVD risk score (QRISK2 or 3) greater than 20%, who are currently treated with statins (31 points).
  4. CVD-04: Percentage of patients aged 29 and under with a total cholesterol greater than 7.5 OR aged 30+ with a total cholesterol greater than 9.0 who have been referred for assessment for familial hypercholesterolaemia (18 points).
  5. CVD-05: Percentage of patients on QOF AF register and a CHA2DS2-VASc score of 2 or more (1 or more for patients that are not female), who were prescribed a DOAC, or, where a DOAC was declined or clinically unsuitable, a Vit K antagonist (66 points).
  6. CVD-06: Number of patients that were prescribed Edoxaban, as a percentage of patients on the QOF AF register with a CHA2DS2-VASc score of 1 or more for men or 2 or more for women and who were prescribed a DOAC (66 points).
  7. VI-01, VI-02, VI-03: Offer flu vaccine to eligible patients (142 points).
  8. HI-01: Percentage of patients on Learning Disability register aged 14+, who received an annual LD Health Check and have a completed Health Action Plan (36 points).
  9. CAN-01: Percentage of lower GI 2WW referrals accompanied by a FIT result, with the result recorded either in the 7 days before or 14 days after the referral (22 points).


Support better patient outcomes in the community through proactive primary care

  1. PC-01: Percentage of patients referred to social prescribing (20 points).
  2. EHCH-02: Percentage of care home residents with a Personalised Care and Support Plan (PCSP) agreed or reviewed (18 points).
  3. EHCH-04: Average number of patient contacts as part of weekly care home round per care home resident (13 points).
  4. EHCH-06: Standardised number of emergency admissions per 100 care home residents aged 18+ (27 points).
  5. AC-02: Standardised number of emergency admissions for specified Ambulatory Care Sensitive Conditions per 1,000 registered patients (111 points).


Support improved patient access to primary care services

  1. ACC-02: Number of online consultations per 1,000 registered patients (18 points).
  2. ACC-06: Standardised percentage of survey respondents indicating that it was “easy” or “very easy” for them to make a general practice appointment, or to seek medical care or advice from their general practice (111 points).
  3. ACC-07: Specialist Advice utilisation rate across twelve specialties identified for accelerated delivery (44 points).
  4. ACC-08: Percentage of patients who waited two weeks or less for a GP appointment (71 points).
  5. ACC-09: Number of referrals to the Community Pharmacist Consultation Service per 1,000 registered patients (27 points).


Deliver better outcomes for patients on medication

  1. SMR-01: Percentage of patients eligible to receive a Structured Medication Review who received a Structured Medication Review (53 points).
  2. SMR-02A: Percentage of patients aged 18+ prescribed both an NSAID and an oral anticoagulant in the 3 months to 1 Apr 2022, who in the 3 months to 1 Apr 2023 were either (i) no longer prescribed an NSAID or (ii) prescribed a gastroprotective in addition to both an NSAID and an oral anticoagulant (4 points).
  3. SMR-02B: Percentage of patients aged 65+ prescribed an NSAID and not an oral anticoagulant in the 3 months to 1 Apr 2022, who in the 3 months to 1 Apr 2023 were either (i) no longer prescribed an NSAID or (ii) prescribed a gastroprotective in addition to an NSAID (4 points).
  4. SMR-02C: Percentage of patients aged 18+ prescribed both an oral anticoagulant and an anti-platelet in the 3 months to 1 Apr 2022, who in the 3 months to 1 Apr 2023 were either (i) no longer prescribed an anti-platelet or (ii) prescribed a gastroprotective in addition to both an oral anticoagulant and an anti-platelet (4 points).
  5. SMR-02D: Percentage of patients aged 18+ prescribed aspirin and another anti-platelet in the 3 months to 1 Apr 2022, who in the 3 months to 1 Apr 2023 were either (i) no longer prescribed aspirin and/or no longer prescribed an anti-platelet or (ii) prescribed a gastroprotective in addition to both aspirin and another anti-platelet (4 points).
  6. SMR-03: Percentage of patients prescribed a DOAC, who received a renal function test and a recording of their weight and Creatinine Clearance Rate, along with a change or confirmation of their medication dose (13 points).
  7. RESP-01: Percentage of patients on the QOF Asthma Register who were regularly prescribed an inhaled corticosteroid over the previous 12 months (31 points)
  8. RESP-02: Percentage of patients on the QOF Asthma Register who received six or more SABA inhaler prescriptions over the previous 12 months (22 points).


Help create a more sustainable NHS

  1. ES-01: Metered Dose Inhaler (MDI) prescriptions as a percentage of all non- salbutamol inhaler prescriptions issued to patients aged 12+ (27 points).
  2. ES-02: Mean carbon emissions per salbutamol inhaler prescribed (44 points).